Results overview: Found 8 records in 0.02 seconds.
Articles, 6 records found
Personal and institutional archives, 2 records found
Articles 6 records found  
1.
5 p, 654.2 KB Educational needs in gastrointestinal cancer : a consensus position paper from the ESMO Gastrointestinal Cancer Faculty / Lordick, Florian (Leipzig University Medical Center) ; Obermannova, Radka (Masaryk University) ; Vola, Doris (European Society for Medical Oncology) ; Douillard, Jean-Yves (European Society for Medical Oncology) ; Mcgregor, Keith (European Society for Medical Oncology) ; Van Cutsem, Eric (University Hospitals Leuven (Bèlgica)) ; Tabernero, Josep (Universitat Autònoma de Barcelona) ; Ciardiello, Fortunato (Second University of Naples) ; Cervantes, Andrés (University of Valencia)
Gastrointestinal (GI) cancers are common in all parts of the world. Effective prevention and early detection of GI cancers are not universally implemented. Therefore, it must be anticipated that the incidence and the mortality of GI cancers will remain high within the next decades. [...]
2019 - 10.1136/esmoopen-2019-000533
ESMO open, Vol. 4 (july 2019)  
2.
9 p, 1023.2 KB Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain : results of a subgroup analysis of the phase 3 RECOURSE trial / Longo Muñoz, Federico (Hospital Universitario Ramón y Cajal (Madrid)) ; Argilés Martínez, Guillem (Hospital Universitari Vall d'Hebron) ; Tabernero, Josep (Hospital Universitari Vall d'Hebron) ; Cervantes, Andrés (Universitat de València) ; Grávalos, Cristina (Hospital Universitario 12 de Octubre (Madrid)) ; Pericay, Carles (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Gil Calle, S. (Hospital Regional Universitario Carlos Haya (Málaga)) ; Mizuguchi, Hirokazu (Taiho Oncology) ; Carrato, Alfredo (Hospital Universitario Ramón y Cajal (Madrid)) ; Limón, María Luisa (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; García Carbonero, Rocio (Hospital Universitario 12 de Octubre (Madrid)) ; Universitat Autònoma de Barcelona
TAS-102 is a combination of the thymidine-based nucleoside analog trifluridine and the thymidine phosphorylase inhibitor tipiracil. Efficacy and safety of TAS-102 in patients with metastatic colorectal cancer (mCRC) refractory or intolerant to standard therapies were evaluated in the phase 3 RECOURSE trial. [...]
2017 - 10.1007/s12094-016-1528-7
Clinical & Translational Oncology, Vol. 19, Issue 2 (February 2017) , p. 227-235  
3.
6 p, 1.4 MB Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients / Sclafani, Francesco (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Chau, Ian (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Cunningham, David (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Lampis, Andrea (The Institute of Cancer Research. Department of Molecular Pathology) ; Hahne, Jens Claus (The Institute of Cancer Research. Department of Molecular Pathology) ; Ghidini, Michele (The Institute of Cancer Research. Department of Molecular Pathology) ; Lote, Hazel (The Institute of Cancer Research. Department of Molecular Pathology) ; Zito, Domenico (The Institute of Cancer Research. Department of Molecular Pathology) ; Tabernero, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Glimelius, Bengt (University of Uppsala. Genetics and Pathology, Experimental and Clinical Oncology. Department of Immunology) ; Cervantes, Andrés (University of Valencia. Biomedical Research Institute INCLIVA. Department of Haematology and Medical Oncology) ; Begum, Ruwaida (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; De Castro, David Gonzalez (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Wilson, Sanna Hulkki (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Peckitt, Clare (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Eltahir, Zakaria (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Wotherspoon, Andrew (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Tait, Diana (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Brown, Gina (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Oates, Jacqueline (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Braconi, Chiara (The Institute of Cancer Research. Department of Cancer Therapeutics) ; Valeri, Nicola (The Institute of Cancer Research. Department of Molecular Pathology) ; Universitat Autònoma de Barcelona
Analysis of a polymorphism in mature microRNA-608 (rs4919510) in rectal cancer patients enrolled in a randomized phase II clinical trial identified patient subpopulations who might benefit from the use of an intensified neo-adjuvant treatment strategy with Cetuximab. [...]
2016 - 10.1093/carcin/bgw073
Carcinogenesis, Vol. 37 (july 2016) , p. 852-857  
4.
9 p, 306.4 KB Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer / Élez Fernández, María Elena (Vall d'Hebron Institut d'Oncologia) ; Hendlisz, A. (Institut Jules Bordet (Belgium)) ; Delaunoit, T. (Centres Hospitaliers Jolimont (Belgium)) ; Sastre, J. (Hospital Clínico San Carlos (Madrid)) ; Cervantes, Andrés (Instituto de Investigación Sanitaria INCLIVA (Valèna, Comunitat Valenciana)) ; Varea, R. (Eli Lilly and Company (Spain)) ; Chao, G. (Eli Lilly and Company (USA)) ; Wallin, J. (Eli Lilly and Company (Suècia)) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
This single-arm phase II study investigated the EGFR monoclonal antibody necitumumab plus modified FOLFOX6 (mFOLFOX6) in first-line treatment of locally advanced or metastatic colorectal cancer (mCRC). [...]
2016 - 10.1038/bjc.2015.480
British Journal of Cancer, Vol. 114 (February 2016) , p. 372-380  
5.
6 p, 225.1 KB Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer : results of the EXPERT-C trial / Sclafani, Francesco (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Chau, I. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Cunningham, D. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Peckitt, C. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Lampis, A. (The Institute of Cancer Research. Division of Molecular Pathology (UK)) ; Hahne, J. C. (The Institute of Cancer Research. Division of Molecular Pathology (UK)) ; Braconi, Chiara (The Institute of Cancer Research. Division of Cancer Therapeutics (UK)) ; Tabernero, Josep (Hospital Universitari Vall d'Hebron) ; Glimelius, B. (University of Uppsala. Department of Immunology, Genetics and Pathology (Sweden)) ; Cervantes, Andrés (Universidad de Valencia. Departamento de Hematología y Oncología Médica) ; Begum, R. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Gonzalez De Castro, David (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Hulkki Wilson, S. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Eltahir, Zakaria (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Wotherspoon, A. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Tait, D. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Brown, Gina (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Oates, J. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Valeri, Nicola (The Institute of Cancer Research. Division of Molecular Pathology (UK)) ; Universitat Autònoma de Barcelona
Lethal-7 (let-7) is a tumour suppressor miRNA which acts by down-regulating several oncogenes including KRAS. A single-nucleotide polymorphism (rs61764370, T > G base substitution) in the let-7 complementary site 6 (LCS-6) of KRAS mRNA has been shown to predict prognosis in early-stage colorectal cancer (CRC) and benefit from anti-epidermal growth factor receptor monoclonal antibodies in metastatic CRC. [...]
2015 - 10.1093/annonc/mdv285
Annals of oncology, Vol. 26, Issue 9 (September 2015) , p. 1936-1941  
6.
8 p, 207.5 KB Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS -mutated metastatic colorectal cancer / Macarulla Mercadé, Teresa (Vall d'Hebron Institut d'Oncologia) ; Cervantes, Andrés (Universidad de Valencia. Biomedical Research Institute (INCLIVA)) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Roselló, Susana (Universidad de Valencia. Biomedical Research Institute (INCLIVA)) ; Van Cutsem, E. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Tejpar, S. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Prenen, H. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Martinelli, E. (Second University of Naples. Department of Experimental and Clinical Medicine) ; Troiani, T. (Second University of Naples. Department of Experimental and Clinical Medicine) ; Laffranchi, B. (Merck Serono SA) ; Jego, V (Merck Serono SA) ; von Richter, O. (Merck KGaA) ; Ciardiello, Fortunato (Second University of Naples. Department of Experimental and Clinical Medicine) ; Universitat Autònoma de Barcelona
The mitogen-activated protein kinase (MAPK) pathway has been implicated in the molecular pathogenesis of human cancers, including metastatic colorectal cancer (mCRC). This provides a rationale for the development of MAPK-targeted agents such as pimasertib. [...]
2015 - 10.1038/bjc.2015.144
British Journal of Cancer, Vol. 112 (June 2015) , p. 1874-1881  

Personal and institutional archives 2 records found  
1.
1 p, 49.6 KB Carta de Rafael Lorente a Andrés Cervantes / Lorente, Rafael ; Cervantes, Andrés
Resposta afirmativa a la petició, per part d'Andrés Cervantes i altres veïns de Palomares, de que Rafael Lorente s'afegeixi a l'equip d'advocats que defensa els interessos dels habitants de la localitat vers l'accident nuclear.
1966  
2.
1 p, 46.9 KB Carta d'Andrés Cervantes, José López, José Flores, Martín Moreno, Manuel González, Antonio Flores y Lorenzo González a Rafael Lorente / Cervantes, Andrés ; Lorente, Rafael
Petició, per part d'alguns veïns de Palomares, a Rafael Lorente, advocat i testimoni presencial de l'accident nuclear de Palomares, de que col·labori amb els advocats que porten el cas.
1966  

See also: similar author names
10 Cervantes, Andres
1 Cervantes, Anton
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.